GNH USA

Europe — EMA

Icatibant Fresenius (Icatibant Acetate)

GNH USA supplies Icatibant Fresenius (Icatibant Acetate), a bradykinin B2 receptor antagonist for acute hereditary angioedema attacks.

Icatibant Acetate

Request sourcing

1
Pack/s

What is Icatibant Acetate?

Icatibant acetate, the active ingredient in Icatibant Fresenius, is a bradykinin B2 receptor antagonist presented as a sterile solution for injection for subcutaneous administration. It is indicated for the treatment of acute attacks of hereditary angioedema (HAE) types I and II in patients with a confirmed diagnosis, providing rapid symptom relief.

GNH USA supplies Icatibant Fresenius as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑controlled distribution across EU and other regulated markets and research institutions.

What is Icatibant Acetate used for?

Icatibant Fresenius is used to treat bradykinin‑mediated hereditary angioedema attacks.

- Acute hereditary angioedema type I: rapid reduction of swelling during an attack. - Acute hereditary angioedema type II: rapid reduction of swelling during an attack. - Hereditary angioedema attacks (any type): alleviation of symptoms and restoration of normal function.

What are the side effects of Icatibant Acetate?

Icatibant Fresenius may cause a range of adverse reactions.

Common Side Effects: - Injection site pain or erythema. - Local swelling or induration at the injection site. - Headache. - Nausea. - Dizziness. - Fatigue.

Serious or Rare Side Effects: - Hypersensitivity reactions, including rash or urticaria. - Anaphylaxis or severe systemic allergic response. - Severe hypotension. - Angioedema unrelated to HAE. - Infection at the injection site.

What precautions apply to Icatibant Acetate?

Before using Icatibant Fresenius, consider the following safety measures.

- Confirm diagnosis: ensure the patient has a documented hereditary angioedema type I or II. - Monitor for hypersensitivity: observe the patient after injection for any allergic signs. - Avoid in patients with known hypersensitivity to icatibant acetate or any excipients. - Use with caution in patients receiving ACE inhibitors, as bradykinin levels may be elevated. - Pregnancy and lactation: limited data are available; weigh potential benefits against unknown risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

What does Icatibant Acetate interact with?

Icatibant Fresenius can interact with other medicines that affect the bradykinin pathway or vascular tone.

Major Interactions (Avoid): - ACE inhibitors: may increase bradykinin levels and raise the risk of angioedema. - C1‑esterase inhibitor concentrates: concurrent use is not recommended due to overlapping mechanisms.

Moderate Interactions (Monitor Closely): - Angiotensin receptor blockers: may modestly increase bradykinin activity. - Estrogen‑containing oral contraceptives: can influence HAE severity and may require closer monitoring. - Other bradykinin‑targeting agents: combined use could alter efficacy or safety profile.

Frequently asked questions

What is Icatibant Fresenius used for?+
Icatibant Fresenius is a prescription injectable medication used to treat acute attacks of hereditary angioedema (HAE) types I and II. It works by rapidly reducing the swelling and pain associated with these bradykinin‑mediated episodes.
How does icatibant acetate work?+
Icatibant acetate is a selective antagonist of the bradykinin B2 receptor. By blocking this receptor on blood‑vessel walls, it prevents bradykinin‑induced vasodilation and increased vascular permeability, which are the primary drivers of swelling in hereditary angioedema.
What is the usual dose of Icatibant Fresenius?+
The dosage and administration schedule for Icatibant Fresenius are determined by the prescribing healthcare professional based on the patient’s clinical condition, severity of the attack, and regulatory guidelines. The prescriber will specify the exact dose and timing.
Is Icatibant Fresenius safe during pregnancy or breastfeeding?+
Safety data for icatibant acetate in pregnancy and lactation are limited. Healthcare providers should evaluate the potential benefits against possible risks before prescribing it to pregnant or nursing women, and use it only if clearly needed.
How do I order Icatibant Fresenius from GNH USA?+
To order Icatibant Fresenius, submit an enquiry on the product page at gnh-usa.com with the required quantity. GNH USA supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and import documentation.
How does Icatibant Fresenius compare with other HAE treatments?+
Icatibant Fresenius is a bradykinin B2 receptor antagonist, whereas other approved HAE therapies include C1‑esterase inhibitor concentrates and kallikrein inhibitors. Icatibant acts directly on the bradykinin pathway, offering rapid symptom relief after subcutaneous injection, while the alternatives work upstream or replace deficient proteins.
What are the storage requirements for Icatibant Fresenius?+
Icatibant Fresenius should be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the solution, as these conditions can affect its stability and efficacy.
How is Icatibant Fresenius administered?+
The medication is supplied as a sterile solution for injection and is administered subcutaneously, typically into the abdomen or thigh. The injection is performed by a trained healthcare professional or, in some cases, by the patient after appropriate instruction.
What are the most serious risks associated with Icatibant Fresenius?+
Serious risks include hypersensitivity reactions such as anaphylaxis, severe hypotension, and rare cases of systemic angioedema unrelated to HAE. Patients should be observed after injection and instructed to seek immediate medical attention if they experience any signs of a severe allergic reaction.
Who should not use Icatibant Fresenius?+
Icatibant Fresenius should not be used by individuals with a known hypersensitivity to icatibant acetate or any of its excipients. Caution is also advised for patients receiving ACE inhibitors or other agents that increase bradykinin levels, and it is generally avoided in unconfirmed diagnoses of HAE.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Icatibant Acetate
Route
Subcutaneous Use
Manufacturer
Fresenius Kabi Polska Sp. Z O.O.
Origin
EU

Related products

Icatibant

Icatibant

Icatibant Acetate

Fresenius Kabi Deutschland Gmbh
EU
Icatibant

Icatibant

Icatibant Acetate

Newbury Pharmaceuticals Ab
EU
Icatibant Adalvo

Icatibant Adalvo

Icatibant Acetate

Adalvo Limited
EU
Icatibant Auxilia

Icatibant Auxilia

Icatibant Acetate

Auxilia Pharma
EU